The Lymphoproliferative Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Lymphoproliferative Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lymphoproliferative Disorders. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lymphoproliferative Disorders and features dormant and discontinued products.

GlobalData tracks 21 drugs in development for Lymphoproliferative Disorders by 21 companies/universities/institutes. The top development phase for Lymphoproliferative Disorders is preclinical with nine drugs in that stage. The Lymphoproliferative Disorders pipeline has 18 drugs in development by companies and three by universities/ institutes. Some of the companies in the Lymphoproliferative Disorders pipeline products market are: Viracta Therapeutics, Innovent Biologics and bluebird bio.

The key targets in the Lymphoproliferative Disorders pipeline products market include Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1).

The key mechanisms of action in the Lymphoproliferative Disorders pipeline product include Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8) with four drugs in Phase I. The Lymphoproliferative Disorders pipeline products include ten routes of administration with the top ROA being Intravenous and eight key molecule types in the Lymphoproliferative Disorders pipeline products market including Gene-Modified Cell Therapy, and Monoclonal Antibody.

Lymphoproliferative Disorders overview

Lymphoproliferative disorders (LPD) constitute a diverse group of diseases marked by uncontrolled lymphocyte production, resulting in monoclonal lymphocytosis, lymphadenopathy, and bone marrow infiltration. Predominantly affecting immunocompromised individuals, these disorders involve two subsets of lymphocytes, T and B cells, leading to immunoproliferative disorders with inherent risks of immunodeficiency and lymphocyte dysregulation. Causative gene mutations, whether iatrogenic or acquired, are identified through somatic or germ-line mutations in ALPS genes (FASL, CASP10, FAS), contributing to defective Fas-mediated apoptosis. Allogeneic hematopoietic stem cell transplantation often offers a cure, while specific treatments vary. Primary-EBV infection-associated hemophagocytic lymphohistiocytosis is managed with steroids, cyclosporine A, and etoposide.

For a complete picture of Lymphoproliferative Disorders’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.